Fig. 4From: Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [11C]CB184, in healthy human volunteersMean decay-corrected TACs of whole blood, plasma, metabolite-corrected plasma, and fraction of intact [11C]CB184 after intravenous injection of [11C]CB184 into human subjects (a). Values for 5 min (b) were extracted from a. Data for the fraction of intact [11C]CB184 represent the mean ± SD of five subjectsBack to article page